Healthline Connects
Healthline Connects

First Medication for Huntington's Chorea Approved

Huntington's disease is a fatal, inherited neurodegenerative disorder marked by disabling chorea. Chorea is a symptom of the disease, manifesting in spasmodic, uncontrollable movements that become disabling. The FDA has now approved the medication tetrabenazine for treatment of chorea offering hope to thousands. Tetrabenazine calms the jerky, uncontrollable movements of the body by its action on amines in the brain. Ninety percent of people with Huntington's disease suffer with chorea, so improvement in their symptoms offers dramatic improvement in their quality of life.

Tetrabenazine does not slow progression of the disease, which affects most people in middle age. Prestwick Pharmaceutical, Inc., a privately held company in Washington D.C., owns the rights to develop and sell tetrabenazine in the US. The company specializes in medications treating chronic CNS disorders. Tetrabenazine has been used in Europe for thirty years.

Xenazine®

  • 1
Was this article helpful? Yes No
Advertisement

About the Author

The Healthline Editorial team writes about the latest health news, policy, and research.

Advertisement
Advertisement